Labcorp Holdings Inc. $LH Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC trimmed its holdings in Labcorp Holdings Inc. (NYSE:LH) by 23.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 382,166 shares of the medical research company’s stock after selling 116,889 shares during the period. Natixis Advisors LLC owned approximately 0.46% of Labcorp worth $109,705,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Caldwell Trust Co acquired a new position in shares of Labcorp in the 2nd quarter valued at $25,000. Financial Gravity Companies Inc. acquired a new stake in shares of Labcorp during the 2nd quarter worth about $26,000. Motco acquired a new stake in shares of Labcorp during the 3rd quarter worth about $32,000. Headlands Technologies LLC raised its holdings in Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after buying an additional 96 shares during the period. Finally, Hantz Financial Services Inc. lifted its position in Labcorp by 48.8% in the third quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after buying an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Stock Down 2.1%

Shares of NYSE LH opened at $270.19 on Monday. The stock has a market cap of $22.26 billion, a P/E ratio of 25.83, a PEG ratio of 1.84 and a beta of 1.01. The business’s fifty day simple moving average is $271.00 and its 200-day simple moving average is $270.20. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.Labcorp’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities analysts predict that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Friday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Friday, February 27th. Labcorp’s dividend payout ratio is presently 27.53%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Morgan Stanley reaffirmed an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Piper Sandler boosted their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Finally, Robert W. Baird boosted their target price on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $304.82.

Insider Activity

In related news, EVP Jonathan C. Meltzer sold 87 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the sale, the executive vice president owned 2,782 shares of the company’s stock, valued at $807,948.44. This trade represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of Labcorp stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total transaction of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares of the company’s stock, valued at $8,619,935.17. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 over the last three months. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.